Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Synopsys CEO Ghazi Sassine sells $6.7m in stock

Synopsys CEO Ghazi Sassine sells $6.7m in stock

Synopsys CEO Ghazi Sassine sold 14,604 shares of the company's common stock on October 15, 2026, generating a total of $6,759,359 from the sale. The shares were sold at prices ranging from $455.060 to $471.325, with a weighted average sale price of $462.843 per share. Prior to the sale, Sassine acquired the shares by exercising non-qualified stock options at a price of $135.88 per share, totaling $1,984,391.

The sale came amid a decline in Synopsys stock, which has dropped roughly 11% over the past week, currently trading at $454.63 with a market capitalization of $89.7 billion. These transactions were executed as part of a pre-arranged Rule 10b5-1 trading plan, and Sassine now directly holds 76,865 shares of Synopsys common stock.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Read the original at investing.com →

More in Finance & Markets

US budget deficit balloons to highest in five years

The US budget deficit grew to almost US$2 trillion over the past year, government data showed Friday, reaching its highest level since 2021 despite President Donald Trump's promises to cut public…

  • US budget deficit hit $1.99 trillion in 2026, highest since 2021
  • Interest payments on debt soared to $1.36 trillion, up $144 billion
  • Revenue from Trump's tariffs failed to materialize as expected

Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Bristol-Myers trades at a significant valuation discount, but its higher leverage and patent risks contrast sharply with Johnson & Johnson's diversified stability.

  • Bristol-Myers Squibb reports $48.2 billion revenue in fiscal year 2025, down 0.2%.
  • Johnson & Johnson reports $94.2 billion revenue in fiscal year 2025, up 6%.
  • Johnson & Johnson has been a Dividend King for 64 consecutive years.

More from Saturday 17 October →